文献速递胃肠动力与功能性疾病胰腺与胆道疾病

胆汁酸在慢性腹泻中的作用

The Role of Bile Acids in Chronic Diarrhea.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

综述阐述胆汁酸作为肠肝循环核心信号,通过法尼醇X受体和G蛋白偶联胆汁酸受体1整合菌群信号;胆汁酸性腹泻常见于回肠切除或疾病、特发性障碍及慢性胰腺炎等吸收不良;诊断基于硒-同型胆酸牛磺酸潴留、48小时粪便胆汁酸排泄或血清7αC4;治疗以胆汁酸螯合剂为主,未来法尼醇X受体激动剂可能有效,部分国家指南推荐确定性诊断优于经验性试验。

要点

  • 胆汁酸通过法尼醇X受体和G蛋白偶联胆汁酸受体1信号通路整合肠肝与菌群信号。
  • 胆汁酸性腹泻常见于回肠切除或疾病、特发性障碍及慢性胰腺炎、乳糜泻等吸收不良。
  • 诊断依据硒-同型胆酸牛磺酸潴留、48小时粪便胆汁酸排泄或血清7αC4。

核心结论

  • 胆汁酸是肠肝通讯的核心信号,并整合菌群来源信号进入肠肝信号通路。
  • 胆汁酸性腹泻常见于回肠切除或疾病、特发性障碍及慢性胰腺炎、乳糜泻等吸收不良。
  • 当前治疗基于胆汁酸螯合剂,未来法尼醇X受体激动剂可能也有效。
  • 部分国家指南推荐对胆汁酸性腹泻进行确定性诊断而非经验性试验。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 胆汁酸通过天然受体法尼醇X受体和G蛋白偶联胆汁酸受体1(GPBAR1,又称Takeda G蛋白偶联受体5)激活的信号通路,增进了对机制和潜在治疗药物的理解。
  • 胆汁酸性腹泻与较高的体重指数、增加的粪便重量和粪便脂肪及结肠传输加速相关。
  • 胆汁酸合成或排泄增加的生化标志物可通过参考实验室检测。
  • 胆汁酸螯合剂作为诊断性试验的最佳条件仍不明确,但此类治疗性试验在临床实践中广泛使用。

关键数值与推荐

  • 诊断基于硒-同型胆酸牛磺酸潴留、48小时粪便胆汁酸排泄或血清7αC4,后者是肝脏胆汁酸合成的标志物。

临床怎么用

  • 当前胆汁酸性腹泻的治疗基于胆汁酸螯合剂。
  • 未来法尼醇X受体激动剂可能也有效。
  • 胆汁酸螯合剂作为诊断性试验的最佳条件仍不明确,但此类治疗性试验在临床实践中广泛使用。
  • 部分国家指南推荐对胆汁酸性腹泻进行确定性诊断而非经验性试验。

局限性

  • 胆汁酸螯合剂作为诊断性试验的最佳条件仍不明确。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bile acids (BAs) are the central signals in enterohepatic communication, and they also integrate microbiota-derived signals into enterohepatic signaling. The tissue distribution and signaling pathways activated by BAs through natural receptors, farsenoid X receptor and G protein-coupled BA receptor 1 (GPBAR1, also known as Takeda G-coupled receptor 5), have led to a greater understanding of the mechanisms and potential therapeutic agents. BA diarrhea is most commonly encountered in ileal resection or disease, in idiopathic disorders (with presentation similar to functional diarrhea or irritable bowel syndrome with diarrhea), and in association with malabsorption such as chronic pancreatitis or celiac disease. Diagnosis of BA diarrhea is based on Se-homocholic acid taurine retention, 48-hour fecal BA excretion, or serum 7αC4; the latter being a marker of hepatic BA synthesis. BA diarrhea tends to be associated with higher body mass index, increased stool weight and stool fat, and acceleration of colonic transit. Biochemical markers of increased BA synthesis or excretion are available through reference laboratories. Current treatment of BA diarrhea is based on BA sequestrants, and, in the future, it is anticipated that farsenoid X receptor agonists may also be effective. The optimal conditions for an empiric trial with BA sequestrants as a diagnostic test are still unclear. However, such therapeutic trials are widely used in clinical practice. Some national guidelines recommend definitive diagnosis of BA diarrhea over empirical trial.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Camilleri M, Vijayvargiya P. The Role of Bile Acids in Chronic Diarrhea. Am J Gastroenterol. 2020. PMID: 32558690. doi:10.14309/ajg.0000000000000696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。